Chimeric OspA genes, proteins, and methods of use thereof

US8623375B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH

Inventors

• Brian A. Crowe · Leobendorf, AT
• Ian Livey · Wien, AT
• Maria O'Rourke · Wiener Neudorf, AT
• Michael Schwendinger · Neusiedl am See, AT

Key dates

• Filing date: May 13, 2011
• Grant date: Jan 7, 2014
• Expiry date: May 13, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.